Skip to content
Open access

Graph Neural Network Model for Predicting Mitochondrial Toxicity via Complementary Molecular Features

Aug 2026 · Journal of Technical Education Science · 0 citations · 23 references

TL;DR

A hybrid Graph Neural Network model for predicting mitochondrial toxicity, a significant contributor to drug-induced liver injury, which effectively captures both the structural and physicochemical properties of compounds by integrating graph embeddings and molecular fingerprints is introduced.

Abstract

In this study, we introduce a hybrid Graph Neural Network model for predicting mitochondrial toxicity, a significant contributor to drug-induced liver injury. This model effectively captures both the structural and physicochemical properties of compounds by integrating graph embeddings and molecular fingerprints. After systematically optimizing the model architecture, we found that the combination of the GATv2Conv convolutional layer, 64 hidden neurons, and a single predictor layer was the most effective configuration for our purposes. When benchmarked against well-established 3D GNN models like DimeNet++ and ViSNet, our hybrid model consistently outperformed them, exhibiting improvements in AUC-ROC by up to 18.3% and 6.2%, respectively. These results emphasize the importance of achieving an optimal balance when integrating features and demonstrate the potential of our hybrid GNN model for computational toxicity prediction. This model could notably expedite drug discovery, reduce dependence on animal testing, and provide valuable insights into molecular toxicity.

Read PDF

Similar papers

#small language model Open access Sep 2026

Language of Toxicity: An eXplainable Artificial Intelligence Approach

Toxicity prediction in small molecules represents a fundamental challenge in drug development and chemical safety assessment. Traditional approaches heavily rely on predefined molecular descriptors or fingerprints, potentially limiting the ability to capture complex and nonlinear structure–activity relationships. Here,...

N. Amoroso, E. Pantaleo, Fulvio Ciriaco et al. · 0 citations
Open access Jan 2026

An algebraic graph neural network model for protein-ligand binding affinity prediction

An Algebraic Graph Neural Network model designed to encode molecular structures into a low-dimensional graph representation while preserving critical biochemical interactions is introduced, demonstrating superior performance in binding affinity prediction compared to state-of-the-art scoring functions.

Augustine Ouru, Xi Chen, Cameron Yeagle et al. · 0 citations
Aug 2026

Predicting circRNA-Drug Sensitivity Using Integrated Hybrid Graph and Molecular Features.

Case studies further validated predicted circRNA-drug associations, including cisplatin, enzalutamide, and sorafenib, against published experimental findings, demonstrating HMCDSP's capacity to reveal clinically relevant biomarkers and inform personalized therapeutic strategies.

Yong-Tian Wang, Wen-Kai Shen, Jiahao Li et al. · 1 citation
#machine learning Preprint Sep 2026

Benchmarking graph-based models for in-silico toxicity prediction in drug discovery

A unified and standardized benchmarking framework for GDL-based toxicity prediction is introduced, systematically evaluating more than 20 representative approaches under consistent experimental conditions and across multiple datasets and partitioning strategies, enabling a fair and reproducible comparison of model perf...

Noel Suarez-Barro, M. Lama, J. C. Vidal · 0 citations
Open access Sep 2026

Interpretable Machine Learning Frameworks for QSAR Modeling: A Comparative Study of Classical Algorithms and Transformer-CNN Architectures

An interpretable Quantitative Structure–Activity Relationship (QSAR) framework that integrates classical machine learning approaches with a hybrid deep learning architecture to model enzyme inhibition using a curated and diverse data set from ChEMBL is developed.

Fatima Ezzahra Belkhanchi, M. Mbarki, S. Chtita et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.